This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Pregabalin
Lyrica is a calcium-channel modulator (α2δ subunit) — same family as gabapentin but ~6× more potent and faster-onset.
Aliases (5)
Overview
What is Pregabalin?
Pregabalin (Lyrica) is a structural analog of GABA developed by Pfizer, FDA-approved for neuropathic pain (diabetic neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunct), and generalized anxiety disorder (in some countries). It is a Schedule V controlled substance.
Key Benefits
Effective for neuropathic pain, generalized anxiety, fibromyalgia, and as anticonvulsant adjunct, with faster onset than gabapentin and predictable absorption. Subjective effects include anxiolysis, sedation, and mild euphoria; carries dependence and abuse potential.
Mechanism of Action
Binds the α2δ subunit of voltage-gated calcium channels (Cav2.1 and Cav2.2), reducing presynaptic calcium influx and decreasing release of excitatory neurotransmitters (glutamate, norepinephrine, substance P). Does not bind GABA-A or GABA-B receptors directly.
Pharmacokinetics
▸Brand options4 known
StatusSchedule V (US DEA, since 2005-07-28) | Class C controlled drug (UK, since 2019-04) | Rx-only most jurisdictions
Peptide Interactions
same broad sedative-anxiolytic family with overlapping dependence profile, GABA-B vs α2δ but additive CNS depression and additive withdrawal severity.
CNS depression stacking, both produce withdrawal syndromes.
same mechanism, no benefit to combining; just dose pregabalin.
all CNS depressants with respiratory or sedation stacking risk.
as a "balancer" — masks sedation, leading users to underestimate impairment.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Onset30-60 min, peak 1-1.5 hr.
- Onset24-48 hr after last dose with chronic use.
- Tapering required for any chronic user — no abrupt discontinuation. Standard taper is 10-25% per week; severe-dependence cases use diazepam bridge protocols (PMC …
Side Effects & Safety 13
Side Effects
- 1Dizziness (up to 30%)
- 2Somnolence/sedation (up to 25% — and 15.8% specifically in pain trials, dose-dependent)
- 3Peripheral edema (up to 12%, especially at higher doses; mechanism unknown)
- 4Weight gain (≥7% body weight gain in 9% of patients vs 2% placebo over 14 weeks; dose- and duration-dependent)
- 5Dry mouth, blurred vision, "thinking abnormal" (cognitive slowing/concentration impairment)
- 6Ataxia, balance disorder (concerning for a combat athlete — direct hit on training quality)
- 7Euphoria (4%) — predictor of misuse trajectory
- 8Constipation, nausea, abdominal pain
- 9Headache, asthenia (fatigue/weakness)
- 10Decreased libido, anorgasmia, erectile dysfunction
- 11Confusion, disorientation
- 12Myoclonus, tremor
- 13Vivid dreams, abnormal dreams
When to Stop
- Angioedema (face/lips/throat swelling — emergency)
- Hypersensitivity reactions (rash, urticaria, dyspnea)
- Suicidal ideation/behavior (FDA black-box class warning for all antiepileptics)
- Rhabdomyolysis (rare reports)
- Thrombocytopenia, PR-interval prolongation
- Severe withdrawal syndrome (seizures, psychosis) on abrupt discontinuation after chronic use
- Opioids + pregabalin: synergistic respiratory depression. Major driver of pregabalin-associated mortality. UK 2024 data: 617 pregabalin-involved deaths E&W, vast majority polysubstance with opioids.
- Alcohol + pregabalin: profound CNS depression, respiratory risk.
- Benzodiazepines + pregabalin: stacked CNS depression, near-blackout doses common in misuse.
- First 2-4 weeks: euphoria/liking trajectory predicts misuse risk (PMC 6709807)
- First 8-12 weeks: weight gain trajectory becomes apparent
- Any chronic use: monitor for tolerance creep, dose escalation requests, mood deterioration on missed doses
- Discontinuation: full taper window 4-12+ weeks depending on dose and duration
References
Federal Register — Schedule V placement of pregabalin (2005-07-28)
original DEA scheduling rule.
View StudyLyrica FDA label (2025 revision)
current US prescribing information.
View StudyPregabalin — Wikipedia
generic launch July 2019, UK Class C April 2019, WHO listing 2018.
View StudyField et al. 2006 — α2δ-1 as analgesic target
molecular target identification.
View StudyPharmacology and mechanism of pregabalin (ScienceDirect)
comprehensive mechanism review.
View StudyBockbrader 2010 — Clinical pharmacokinetics of pregabalin
bioavailability, half-life, renal clearance data.
View StudyPfizer fibromyalgia approval press release
first FDA-approved fibromyalgia drug.
View StudyPregabalin abuse/dependence in opioid-addicted patients (PMC)
Switzerland methadone-maintenance abuse data.
View StudyPregabalin misuse case series (Frontiers Psychiatry 2025)
drug dependence case literature.
View StudyMcNeilage et al. 2026 — Pregabalin disproportionality analysis (Br J Clin Pharmacol)
Australian pharmacovigilance signal for dependence/withdrawal/suicidality/psychosis.
View StudyPregabalin abuse + diazepam withdrawal protocol (PMC)
clinical taper guidance.
View StudyEuphoria reporting and pregabalin response (PMC)
early-treatment euphoria as misuse predictor.
View StudyPregabalin: range of misuse-related questions (PMC)
misuse epidemiology review.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.